Novel Anti-Inflammatory Approaches to COPD

References

• Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a lancet commission. Lancet. 2022;400(10356):921–972. doi:10.1016/S0140-6736(22)01273-9
   PubMed Web of Science ®Google Scholar
• Gamble E, Qiu Y, Wang D, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J. 2006;27(2):293–299. doi:10.1183/09031936.06.00027705
   PubMed Web of Science ®Google Scholar
• Deng F, Zhong S, Yu C, et al. Abnormal neutrophil polarization in chronic obstructive pulmonary disease and how cigarette smoke extracts attract neutrophils. Ann Transl Med. 2022;10(8):472. doi:10.21037/atm-22-1480
   PubMed Web of Science ®Google Scholar
• David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
   PubMed Web of Science ®Google Scholar
• Burgoyne RA, Fisher AJ, Borthwick LA. The role of epithelial damage in the pulmonary immune response. Cells. 2021;10(10):2763. doi:10.3390/cells10102763
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. doi:10.1016/j.coph.2020.11.003
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opin Pharmacother. 2022;23(8):917–927. doi:10.1080/14656566.2022.2076592
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol. 2017;237:93–115. doi:10.1007/164_2016_62
   PubMedGoogle Scholar
• Adcock IM, Bhatt SP, Balkissoon R, Wise RA. The use of inhaled corticosteroids for patients with COPD who continue to smoke cigarettes: an evaluation of current practice. Am J Med. 2022;135(3):302–312. doi:10.1016/j.amjmed.2021.09.006
   PubMed Web of Science ®Google Scholar
• Plumb J, Gaffey K, Kane B, et al. Reduced glucocorticoid receptor expression and function in airway neutrophils. Int Immunopharmacol. 2012;12(1):26–33. doi:10.1016/j.intimp.2011.10.006
   PubMed Web of Science ®Google Scholar
• Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134(2):314–322. doi:10.1016/j.jaci.2014.02.001
   PubMed Web of Science ®Google Scholar
• Li LB, Leung DY, Martin RJ, Goleva E. Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor beta in steroid-resistant asthma. Am J Respir Crit Care Med. 2010;182(7):877–883. doi:10.1164/rccm.201001-0015OC
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731–741. doi:10.1016/S2213-2600(16)30148-5
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Annibale R, Russo F, Cazzola M. Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Rev Clin Pharmacol. 2021;14(8):1015–1027. doi:10.1080/17512433.2021.1925537
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold? Semin Respir Crit Care Med. 2015;36(4):508–522. doi:10.1055/s-0035-1555611
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18(7):454–466. doi:10.1038/s41577-018-0006-6
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40(3):724–741. doi:10.1183/09031936.00213711
   PubMed Web of Science ®Google Scholar
• Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol. 2012;19(4):681–692. doi:10.1007/s12350-012-9547-4
   PubMed Web of Science ®Google Scholar
• Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–770. doi:10.1038/nrd2638
   PubMed Web of Science ®Google Scholar
• Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926–934. doi:10.1378/chest.126.3.926
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–469. doi:10.1164/rccm.200501-147OC
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934. doi:10.1164/rccm.200607-995OC
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Maltais F, et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142–148. doi:10.1136/thoraxjnl-2012-202432
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG. An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biologics. 2021;15:363–374. doi:10.2147/BTT.S295409
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Puxeddu E, et al. Emerging biological therapies for treating chronic obstructive pulmonary disease: a pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018;50:28–37. doi:10.1016/j.pupt.2018.03.004
   PubMed Web of Science ®Google Scholar
• Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13(4):290–314. doi:10.1038/nrd4228
   PubMed Web of Science ®Google Scholar
• Jin SL, Goya S, Nakae S, et al. Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2010;126(6):1252–9.e12. doi:10.1016/j.jaci.2010.08.014
   PubMed Web of Science ®Google Scholar
• Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263–2273. doi:10.1161/CIRCULATIONAHA.110.981738
   PubMed Web of Science ®Google Scholar
• Lam M, Bourke JE. A new pathway to airway relaxation: targeting the “other” cyclase in asthma. Am J Respir Cell Mol Biol. 2020;62(1):3–4. doi:10.1165/rcmb.2019-0274ED
   PubMed Web of Science ®Google Scholar
• Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2014;165(3):152–164. doi:10.1159/000368800
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016;11(7):733–744. doi:10.1080/17460441.2016.1184642
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016;15(8):1133–1146. doi:10.1080/14740338.2016.1199683
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? Drugs. 2014;74(17):1983–1992. doi:10.1007/s40265-014-0303-8
   PubMed Web of Science ®Google Scholar
• Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M. New avenues for phosphodiesterase inhibitors in asthma. J Exp Pharmacol. 2021;13:291–302. doi:10.2147/JEP.S242961
   PubMedGoogle Scholar
• Phillips JE. Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases. Front Pharmacol. 2020;11:259. doi:10.3389/fphar.2020.00259
   PubMed Web of Science ®Google Scholar
• Singh D, Emirova A, Francisco C, Santoro D, Govoni M, Nandeuil MA. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. Respir Res. 2020;21(1):246. doi:10.1186/s12931-020-01512-y
   PubMed Web of Science ®Google Scholar
• Nguyen HO, Salvi V, Tiberio L, et al. The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation. J Transl Med. 2022;20(1):203. doi:10.1186/s12967-022-03402-x
   PubMed Web of Science ®Google Scholar
• Li G, He D, Cai X, et al. Advances in the development of phosphodiesterase-4 inhibitors. Eur J Med Chem. 2023;250:115195. doi:10.1016/j.ejmech.2023.115195
   PubMedGoogle Scholar
• Paes D, Hermans S, van den Hove D, Vanmierlo T, Prickaerts J, Carlier A. Computational investigation of the dynamic control of cAMP signaling by PDE4 isoform types. Biophys J. 2022;121(14):2693–2711. doi:10.1016/j.bpj.2022.06.019
   PubMed Web of Science ®Google Scholar
• Page C, Cazzola M. Bifunctional drugs for the treatment of respiratory diseases. Handb Exp Pharmacol. 2017;237:197–212. doi:10.1007/164_2016_69
   PubMedGoogle Scholar
• Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol. 2014;114(5):365–376. doi:10.1111/bcpt.12209
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, Matera MG. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019;28(10):827–833. doi:10.1080/13543784.2019.1661990
   PubMed Web of Science ®Google Scholar
• Barjaktarevic IZ, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, significantly reduces annualized exacerbations and delays the time to first exacerbation in COPD: pooled sub-group analyses of ENHANCE-1 and ENHANCE-2 phase 3 trials. Am J Respir Crit Care Med. 2023;207:A5008. doi:10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A5008
   Google Scholar
• Sciurba F, Anzueto A, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, improves lung function, symptoms, quality of life and reduces exacerbation rate and risk in patients with COPD: results from replicate phase 3 trials. Am J Respir Crit Care Med. 2023;207:A5005. doi:10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A5005
   Google Scholar
• Anzueto A, Rheault T, Bengtsson T, Rickard K. Treatment with ensifentrine, a dual PDE3 and PDE4 inhibitor, significantly reduced exacerbation rate and risk in subjects with COPD: sub-group results from the phase 3 trial, ENHANCE-2. Am J Respir Crit Care Med. 2023;207:A4998. doi:10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A4998
   Google Scholar
• Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009;121(1):55–68. doi:10.1016/j.pharmthera.2008.10.005
   PubMed Web of Science ®Google Scholar
• Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2005;289(2):L322–L328. doi:10.1152/ajplung.00039.2005
   PubMed Web of Science ®Google Scholar
• Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1001–1011. doi:10.1164/rccm.201405-0992OC
   PubMed Web of Science ®Google Scholar
• Lazaar AL, Miller BE, Donald AC, et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res. 2020;21(1):149. doi:10.1186/s12931-020-01401-4
   PubMed Web of Science ®Google Scholar
• Keir HR, Richardson H, Fillmore C, et al. CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Res. 2020;6(4):00583–2020. doi:10.1183/23120541.00583-2020
   PubMedGoogle Scholar
• Mattos MS, Ferrero MR, Kraemer L, et al. CXCR1 and CXCR2 inhibition by ladarixin improves neutrophil-dependent airway inflammation in mice. Front Immunol. 2020;11:566953. doi:10.3389/fimmu.2020.566953
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Sciacqua A, Terracciano R, Pelaia G. Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives. Expert Rev Respir Med. 2020;14(5):485–491. doi:10.1080/17476348.2020.1732821
   PubMed Web of Science ®Google Scholar
• Pascoe S, Costa M, Marks-Konczalik J, McKie E, Yang S, Scherbovsky PS. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD. Respir Med. 2017;130:20–26. doi:10.1016/j.rmed.2017.07.002
   PubMed Web of Science ®Google Scholar
• Higham A, Karur P, Jackson N, Cunoosamy DM, Jansson P, Singh D. Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells. Int J Chron Obstruct Pulmon Dis. 2018;13:1279–1288. doi:10.2147/COPD.S159936
   PubMed Web of Science ®Google Scholar
• Patel NR, Cunoosamy DM, Fagerås M, et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018;13:1009–1019. doi:10.2147/COPD.S150576
   PubMed Web of Science ®Google Scholar
• Charron CE, Russell P, Ito K, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017;50(4):1700188. doi:10.1183/13993003.00188-2017
   PubMed Web of Science ®Google Scholar
• Strâmbu IR, Kobalava ZD, Magnusson BP, MacKinnon A, Parkin JM. Phase II study of single/repeated doses of acumapimod (BCT197) to treat acute exacerbations of COPD. COPD. 2019;16(5–6):344–353. doi:10.1080/15412555.2019.1682535
   PubMedGoogle Scholar
• Wedzicha JA, MacKinnon A, Parkin JM. Effectiveness of acumapimod oral p38 inhibitor in the treatment of acute severe exacerbations of COPD: results of the AETHER phase II trial. Am J Respir Crit Care Med. 2018;197:A7710.
   Web of Science ®Google Scholar
• Yu H, Su X, Lei T, et al. Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD. Front Pharmacol. 2022;13:950035. doi:10.3389/fphar.2022.950035
   PubMed Web of Science ®Google Scholar
• Wang C, Zhou J, Wang J, et al. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther. 2020;5(1):248. doi:10.1038/s41392-020-00345-x
   PubMed Web of Science ®Google Scholar
• Onions ST, Ito K, Charron CE, et al. Discovery of narrow spectrum kinase inhibitors: new therapeutic agents for the treatment of COPD and steroid-resistant asthma. J Med Chem. 2016;59(5):1727–1746. doi:10.1021/acs.jmedchem.5b01029
   PubMed Web of Science ®Google Scholar
• Curran A, Charron C, Russell P, Hava D. PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients. Eur Respir J. 2018;52:A5247. doi:10.1183/13993003.congress-2018.PA5247
   Web of Science ®Google Scholar
• Wasilewski M, Clayton R, Singh D, Perry J, Curran A. Safety and tolerability of PUR1800, an orally inhaled narrow spectrum kinase inhibitor, in patients with stable chronic obstructive pulmonary disease (COPD). J Allergy Clin Immunol. 2023;151(2 suppl):AB10. doi:10.1016/j.jaci.2022.12.062
   Web of Science ®Google Scholar
• Gupta V, Khan A, Higham A, et al. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils. Int Immunopharmacol. 2016;35:155–162. doi:10.1016/j.intimp.2016.03.027
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1176–1186. doi:10.1164/rccm.201008-1285OC
   PubMed Web of Science ®Google Scholar
• Stark AK, Chandra A, Chakraborty K, et al. PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat Commun. 2018;9(1):3174. doi:10.1038/s41467-018-05674-8
   PubMedGoogle Scholar
• Cahn A, Hamblin JN, Robertson J, et al. An inhaled PI3Kδ inhibitor improves recovery in acutely exacerbating COPD patients: a randomized trial. Int J Chron Obstruct Pulmon Dis. 2021;16:1607–1619. doi:10.2147/COPD.S309129
   PubMed Web of Science ®Google Scholar
• Fahy WA, Homayoun-Valiani F, Cahn A, et al. Nemiralisib in patients with an acute exacerbation of COPD: placebo-controlled, dose-ranging study. Int J Chron Obstruct Pulmon Dis. 2021;16:1637–1646. doi:10.2147/COPD.S309320
   PubMed Web of Science ®Google Scholar
• Begg M, Hamblin JN, Jarvis E, et al. Exploring PI3Kδ molecular pathways in stable COPD and following an acute exacerbation, two randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2021;16:1621–1636. doi:10.2147/COPD.S309303
   PubMed Web of Science ®Google Scholar
• Sadiq MW, Asimus S, Belvisi MG, et al. Characterisation of pharmacokinetics, safety, and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. Br J Clin Pharmacol. 2022;88(1):260–270. doi:10.1111/bcp.14956
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Maestrelli P, Roggeri A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1994;149(3 Pt 1):803–810. doi:10.1164/ajrccm.149.3.7509705
   PubMed Web of Science ®Google Scholar
• Blidberg K, Palmberg L, James A, et al. Adhesion molecules in subjects with COPD and healthy non-smokers: a cross sectional parallel group study. Respir Res. 2013;14(1):47. doi:10.1186/1465-9921-14-47
   PubMedGoogle Scholar
• Watz H, Bock D, Meyer M, et al. Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD. Pulm Pharmacol Ther. 2013;26(2):265–270. doi:10.1016/j.pupt.2012.12.003
   PubMed Web of Science ®Google Scholar
• Tvaroška I, Selvaraj C, Koča J. Selectins - The two Dr. Jekyll and Mr. Hyde faces of adhesion molecules - A review. Molecules. 2020;25(12):2835. doi:10.3390/molecules25122835
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M, Ora J, Rogliani P. Biologic therapies for chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2023;23(2):163–173. doi:10.1080/14712598.2022.2160238
   PubMed Web of Science ®Google Scholar
• Higham A, Beech A, Wolosianka S, et al. Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease. Allergy. 2021;76(6):1861–1864. doi:10.1111/all.14661
   PubMed Web of Science ®Google Scholar
• Eich A, Urban V, Jutel M, et al. A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease. COPD. 2017;14(5):476–483. doi:10.1080/15412555.2017.1335697
   PubMedGoogle Scholar
• Murugaiah V, Tsolaki AG, Kishore U. Collectins: innate Immune pattern recognition molecules. Adv Exp Med Biol. 2020;1204:75–127. doi:10.1007/978-981-15-1580-4_4
   PubMed Web of Science ®Google Scholar
• Watson A, Madsen J, Clark HW. SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties. Front Immunol. 2021;11:622598. doi:10.3389/fimmu.2020.622598
   PubMed Web of Science ®Google Scholar
• Pilecki B, Wulf-Johansson H, Støttrup C, et al. Surfactant protein D deficiency aggravates cigarette smoke-induced lung inflammation by upregulation of ceramide synthesis. Front Immunol. 2018;9:3013. doi:10.3389/fimmu.2018.03013
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Saha S, Siva R, et al. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration. 2009;78(3):256–262. doi:10.1159/000221902
   PubMed Web of Science ®Google Scholar
• Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667–670. doi:10.1111/resp.12475
   PubMed Web of Science ®Google Scholar
• Caramori G, Adcock IM, Di Stefano A, Chung KF. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397–412. doi:10.2147/COPD.S42544
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755–1770. doi:10.2147/COPD.S294333
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8(2):158–170. doi:10.1016/S2213-2600(19)30338-8
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901. doi:10.1016/S2213-2600(14)70187-0
   PubMed Web of Science ®Google Scholar
• Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295. doi:10.1172/JCI85664
   PubMed Web of Science ®Google Scholar
• Lange P, Ahmed E, Lahmar ZM, Martinez FJ, Bourdin A. Natural history, and mechanisms of COPD. Respirology. 2021;26(4):298–321. doi:10.1111/resp.14007
   PubMedGoogle Scholar
• Sun J, Liu T, Yan Y, et al. The role of Th1/Th2 cytokines played in regulation of specific CD4+ Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. Scand J Immunol. 2018;88(1):e12674. doi:10.1111/sji.12674
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023. doi:10.1056/NEJMoa2303951
   Web of Science ®Google Scholar
• Zhang K, Shan L, Rahman MS, Unruh H, Halayko AJ, Gounni AS. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L375–L382. doi:10.1152/ajplung.00045.2007
   PubMed Web of Science ®Google Scholar
• Calvén J, Yudina Y, Hallgren O, et al. Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases. J Innate Immun. 2012;4(1):86–99. doi:10.1159/000329131
   PubMed Web of Science ®Google Scholar
• Elder MJ, Webster SJ, Williams DL, Gaston JS, Goodall JC. TSLP production by dendritic cells is modulated by IL-1β and components of the endoplasmic reticulum stress response. Eur J Immunol. 2016;46(2):455–463. doi:10.1002/eji.201545537
   PubMed Web of Science ®Google Scholar
• Cohen ES, Scott IC, Majithiya JB, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. 2015;6(1):8327. doi:10.1038/ncomms9327
   PubMed Web of Science ®Google Scholar
• Cayrol C. IL-33, an Alarmin of the IL-1 Family involved in allergic and non allergic inflammation: focus on the mechanisms of regulation of its activity. Cells. 2021;11(1):107. doi:10.3390/cells11010107
   PubMed Web of Science ®Google Scholar
• Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692. doi:10.3389/fimmu.2019.00692
   PubMed Web of Science ®Google Scholar
• Tworek D, Majewski S, Szewczyk K, et al. The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD. Respir Res. 2018;19(1):108. doi:10.1186/s12931-018-0807-y
   PubMed Web of Science ®Google Scholar
• Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288–1298. doi:10.1016/S2213-2600(21)00167-3
   PubMed Web of Science ®Google Scholar
• Yousuf AJ, Mohammed S, Carr L, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022;10(5):469–477. doi:10.1016/S2213-2600(21)00556-7
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, Matera MG. Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease. Drugs Future. 2023;48(2):101–109. doi:10.1358/dof.2023.48.2.3474010
   Web of Science ®Google Scholar
• Scott IC, England E, Rees DG, et al. Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Eur Respir J. 2022;60:2467. doi:10.1183/13993003.congress-2022.246
   Google Scholar
• Christopoulou ME, Papakonstantinou E, Stolz D. Matrix metalloproteinases in chronic obstructive pulmonary disease. Int J Mol Sci. 2023;24(4):3786. doi:10.3390/ijms24043786
   PubMedGoogle Scholar
• Fingleton B. Matrix metalloproteinases as regulators of inflammatory processes. Biochim Biophys Acta Mol Cell Res. 2017;1864(11 Pt A):2036–2042. doi:10.1016/j.bbamcr.2017.05.010
   PubMed Web of Science ®Google Scholar
• Gharib SA, Manicone AM, Parks WC. Matrix metalloproteinases in emphysema. Matrix Biol. 2018;73:34–51. doi:10.1016/j.matbio.2018.01.018
   PubMed Web of Science ®Google Scholar
• Dahl R, Titlestad I, Lindqvist A, et al. Effects of an oral MMP-9 and −12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther. 2012;25(2):169–177. doi:10.1016/j.pupt.2011.12.011
   PubMed Web of Science ®Google Scholar
• Baggio C, Velazquez JV, Fragai M, Nordgren TM, Pellecchia M. Therapeutic targeting of MMP-12 for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2020;63(21):12911–12920. doi:10.1021/acs.jmedchem.0c01285
   PubMed Web of Science ®Google Scholar
• Li H, Ezra DG, Burton MJ, Bailly M. Doxycycline prevents matrix remodeling and contraction by trichiasis-derived conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2013;54(7):4675–4682. doi:10.1167/iovs.13-11787
   PubMedGoogle Scholar
• Ham J, Kim J, Ko YG, Kim HY. The dynamic contribution of neutrophils in the chronic respiratory diseases. Allergy Asthma Immunol Res. 2022;14(4):361–378. doi:10.4168/aair.2022.14.4.361
   PubMed Web of Science ®Google Scholar
• Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002–2004. doi:10.1126/science.277.5334.2002
   PubMed Web of Science ®Google Scholar
• Kuna P, Jenkins M, O’Brien CD, Fahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. 2012;106(4):531–539. doi:10.1016/j.rmed.2011.10.020
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Aquino TO, O’Brien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD. 2012;9(2):111–120. doi:10.3109/15412555.2011.641803
   PubMedGoogle Scholar
• Voynow JA, Zheng S, Kummarapurugu AB. Glycosaminoglycans as multifunctional anti-elastase and anti-inflammatory drugs in cystic fibrosis lung disease. Front Pharmacol. 2020;11:1011. doi:10.3389/fphar.2020.01011
   PubMed Web of Science ®Google Scholar
• Voynow JA, Shinbashi M. Neutrophil elastase and chronic lung disease. Biomolecules. 2021;11(8):1065. doi:10.3390/biom11081065
   PubMed Web of Science ®Google Scholar
• Shute JK, Calzetta L, Cardaci V, Di Toro S, Page CP, Cazzola M. Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: a pilot study. Pulm Pharmacol Ther. 2018;48:88–96. doi:10.1016/j.pupt.2017.10.001
   PubMed Web of Science ®Google Scholar
• Margaroli C, Madison MC, Viera L, et al. An in vivo model for extracellular vesicle-induced emphysema. JCI Insight. 2022;7(4):e153560. doi:10.1172/jci.insight.153560
   PubMedGoogle Scholar
• Crocetti L, Quinn MT, Schepetkin IA, Giovannoni MP. A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014–2018) and their therapeutic applications. Expert Opin Ther Pat. 2019;29(7):555–578. doi:10.1080/13543776.2019.1630379
   PubMed Web of Science ®Google Scholar
• Palmér R, Mäenpää J, Jauhiainen A, et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther. 2018;104(6):1155–1164. doi:10.1002/cpt.1053
   PubMed Web of Science ®Google Scholar
• Miller BE, Mayer RJ, Goyal N, et al. Epithelial desquamation observed in a Phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017;83(12):2813–2820. doi:10.1111/bcp.13398
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–2137. doi:10.1056/NEJMoa2021713
   PubMed Web of Science ®Google Scholar
• Long MB, Chalmers JD. Treating neutrophilic inflammation in airways diseases. Arch Bronconeumol. 2022;58(6):463–465. doi:10.1016/j.arbres.2021.11.003
   PubMed Web of Science ®Google Scholar
• Kim WD, Chi HS, Choe KH, Kim WS, Hogg JC, Sin DD. The role of granzyme B containing cells in the progression of chronic obstructive pulmonary disease. Tuberc Respir Dis. 2020;83(Supple 1):S25–S33. doi:10.4046/trd.2020.0089
   PubMedGoogle Scholar
• Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell. 2011;44(2):265–278. doi:10.1016/j.molcel.2011.07.037
   PubMed Web of Science ®Google Scholar
• Aslam MS, Yuan L. Serpina3n: potential drug and challenges, mini review. J Drug Target. 2020;28(4):368–378. doi:10.1080/1061186X.2019.1693576
   PubMed Web of Science ®Google Scholar
• Marcet-Palacios M, Ewen C, Pittman E, et al. Design and characterization of a novel human Granzyme B inhibitor. Protein Eng Des Sel. 2015;28(1):9–17. doi:10.1093/protein/gzu052
   PubMed Web of Science ®Google Scholar
• Shen Y, Zeglinski MR, Turner CT, et al. Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing. Exp Mol Med. 2018;50(5):1–11. doi:10.1038/s12276-018-0095-0
   Google Scholar
• Hirst CE, Buzza MS, Bird CH, et al. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol. 2003;170(2):805–815. doi:10.4049/jimmunol.170.2.805
   PubMed Web of Science ®Google Scholar
• Du W, Mohammadpour H, O’Neill RE, et al. Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect. Oncoimmunology. 2017;7(3):e1397247. doi:10.1080/2162402X.2017.1397247
   PubMed Web of Science ®Google Scholar
• Ikram S, Ahmad J, Durdagi S. Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target. J Mol Graph Model. 2020;95:107462. doi:10.1016/j.jmgm.2019.107462
   PubMed Web of Science ®Google Scholar
• Cazzola M, Stolz D, Rogliani P, Matera MG. α1-Antitrypsin deficiency and chronic respiratory disorders. Eur Respir Rev. 2020;29(155):190073. doi:10.1183/16000617.0073-2019
   PubMed Web of Science ®Google Scholar
• Stolk J, Tov N, Chapman KR, et al. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;54(5):1900673. doi:10.1183/13993003.00673-2019
   PubMed Web of Science ®Google Scholar
• Tumpara S, Martinez-Delgado B, Gomez-Mariano G, et al. The delivery of α1-antitrypsin therapy through transepidermal route: worthwhile to explore. Front Pharmacol. 2020;11:983. doi:10.3389/fphar.2020.00983
   PubMed Web of Science ®Google Scholar
• Remih K, Amzou S, Strnad P. Alpha1-antitrypsin deficiency: new therapies on the horizon. Curr Opin Pharmacol. 2021;59:149–156. doi:10.1016/j.coph.2021.06.001
   PubMed Web of Science ®Google Scholar
• Zou Y, Chen X, He B, et al. Neutrophil extracellular traps induced by cigarette smoke contribute to airway inflammation in mice. Exp Cell Res. 2020;389(1):111888. doi:10.1016/j.yexcr.2020.111888
   PubMed Web of Science ®Google Scholar
• Trivedi A, Khan MA, Bade G, Talwar A. Orchestration of neutrophil extracellular traps (NETs), a unique innate immune function during chronic obstructive pulmonary disease (COPD) development. Biomedicines. 2021;9(1):53. doi:10.3390/biomedicines9010053
   PubMed Web of Science ®Google Scholar
• Grabcanovic-Musija F, Obermayer A, Stoiber W, et al. Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation. Respir Res. 2015;16(1):59. doi:10.1186/s12931-015-0221-7
   PubMedGoogle Scholar
• Keir HR, Chalmers JD. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur Respir Rev. 2022;31(163):210241. doi:10.1183/16000617.0241-2021
   PubMed Web of Science ®Google Scholar
• Tanner L, Single AB. Animal Models Reflecting chronic obstructive pulmonary disease and related respiratory disorders: translating pre-clinical data into clinical relevance. J Innate Immun. 2020;12(3):203–225. doi:10.1159/000502489
   PubMed Web of Science ®Google Scholar
• Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014;18(4):381–388. doi:10.1007/s40291-014-0100-9
   PubMed Web of Science ®Google Scholar
• Xu X, Huang K, Dong F, et al. The heterogeneity of inflammatory response and emphysema in chronic obstructive pulmonary disease. Front Physiol. 2021;12:783396. doi:10.3389/fphys.2021.783396
   PubMed Web of Science ®Google Scholar
• Calzetta L, Aiello M, Frizzelli A, et al. Stem cell-based regenerative therapy and derived products in COPD: a systematic review and meta-analysis. Cells. 2022;11(11):1797. doi:10.3390/cells11111797
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Sierra-Párraga JM, Quintana E, López-Campos JL. CFTR dysfunction and targeted therapies: a vision from non-cystic fibrosis bronchiectasis and COPD. J Cyst Fibros. 2022;21(5):741–744. doi:10.1016/j.jcf.2022.04.018
   PubMed Web of Science ®Google Scholar